Drugs used to target HER2-positive invasive breast cancer may also be successful in treating women in the first stages of the disease, researchers at The University of Nottingham have discovered. The findings, published in the British Journal of Cancer and led by experts in the University’s School of Medicine, suggest that extending anti-HER2 drugs to